According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM ) is S$4.83 Million. In 2023 the company made a revenue of S$0.74 Million an increase over the revenue in the year 2022 that were of -S$6.28 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.